Tissue Penetration

Larsen MT, Kuhlmann M, Hvam ML, Howard KA. Albumin-based drug delivery: harnessing nature to cure disease. Mol Cell Ther. (2016) 4:3.

Vosjan MJWD, Vercammen J, Kolkman JA, Stigter-van Walsum M, Revets H, van Dongen GAMS. Nanobodies targeting the hepatocyte growth factor: potential new drugs for molecular cancer therapy. Mol Cancer Ther. 2012;11:1017-1025.

Neumann E, Frei E, Funk D, Becker MD, Schrenk HH, Müller-Ladner U, Fiehn C. Native albumin for targeted drug delivery. Expert Opin Drug Deliv. 2010 Aug;7(8):915-25.

Coppieters K, Dreier T, Silence K, Haard HD, Lauwereys M, Casteels P, Beirnaert E, Jonckheere H, Wiele CV, Staelens L, Hostens J, Revets H, Remaut E, Elewaut D, Rottiers P.  Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis.  Arthritis Rheum. 2006 Jun; 54 (6): 1856-66.

Gibbs WW.  Nanobodies.  Sci Am. 2005 Aug; 293 (2): 78-83.

Wunder A, Müller-Ladner U, Stelzer EH, Funk J, Neumann E, Stehle G, Pap T, Sinn H, Gay S, Fiehn C. Albumin-based drug delivery as novel therapeutic approach for rheumatoid arthritis. J Immunol. 2003 May 1;170(9):4793-801.

Muyldermans S.  Single domain camel antibodies: current status.  J Biotechnol. 2001 Jun; 74 (4): 277-302.

< back